Loading…

Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions

Ocular discomforts involve anterior/posterior-segment diseases, symptomatic distress and associated inflammations and severe retinal disorders. Conventionally, the formulations such as eye drops, eye solutions, eye ointments and lotions, etc. were used as modalities to attain relief from such ocular...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2017-12, Vol.268, p.19-39
Main Authors: Lalu, Lida, Tambe, Vishakha, Pradhan, Deepak, Nayak, Kritika, Bagchi, Suchandra, Maheshwari, Rahul, Kalia, Kiran, Tekade, Rakesh Kumar
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c402t-25909338e82d024bd497ff170de8b6841fec892fd7e581c252ce23c3921707483
cites cdi_FETCH-LOGICAL-c402t-25909338e82d024bd497ff170de8b6841fec892fd7e581c252ce23c3921707483
container_end_page 39
container_issue
container_start_page 19
container_title Journal of controlled release
container_volume 268
creator Lalu, Lida
Tambe, Vishakha
Pradhan, Deepak
Nayak, Kritika
Bagchi, Suchandra
Maheshwari, Rahul
Kalia, Kiran
Tekade, Rakesh Kumar
description Ocular discomforts involve anterior/posterior-segment diseases, symptomatic distress and associated inflammations and severe retinal disorders. Conventionally, the formulations such as eye drops, eye solutions, eye ointments and lotions, etc. were used as modalities to attain relief from such ocular discomforts. However, eye allows limited access to these traditional formulations due to its unique anatomical structure and dynamic ocular environment and therefore calls for improvement in disease intervention. To address these challenges, development of nanotechnology based nanomedicines and novel nanosystems (liposomes, cubosomes, polymeric and lipidic nanoparticles, nanoemulsions, spanlastics and nano micelles) are currently in progress (some of them are already marketed such as Eye-logic liposomal eye spray@Naturalife, Ireland). Today, it is one of the central concept in designing more accessible formulations for deeper segments of the eyes. These nanosystems has largely enabled the availability of medicaments at required site in a required concentration without inversely affecting the eye tissues; and therefore, attaining the excessive considerations from the formulation scientists and pharmacologists worldwide. The entrapment of drugs, genes, and proteins inside these novel systems is the basis that works at the bio-molecular level bestows greater potential to eradicate disease causatives. In this review, we highlighted the recent attempts of nanotechnology-based systems for treating and managing various ocular ailments. The progress described herein may pave the way to new, highly effective and vital ocular nanosystems. [Display omitted]
doi_str_mv 10.1016/j.jconrel.2017.07.035
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1924890381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365917307459</els_id><sourcerecordid>1924890381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-25909338e82d024bd497ff170de8b6841fec892fd7e581c252ce23c3921707483</originalsourceid><addsrcrecordid>eNqFkE1vEzEQhi1E1aalPwHkI5cN_ljHNheEIqBIVbnA2XLsMXW0awfbW6n_vo4SuCKNNId53hnNg9BbStaU0M2H_XrvciowrRmhck16cfEKraiSfBi1Fq_RqnNq4Buhr9B1rXtCiOCjvERXTEmxYZKt0PSQn2DCyaZcn2uDueKQC26PgFsB22ZIDeeAs1smW3BMYbLzbFvM6SPeLqUc5wdbrI-_e9Ymj8PSlgK4QAVb3CP2sYA7BuobdBHsVOH23G_Qr69ffm7vhvsf375vP98PbiSsDUxoojlXoJgnbNz5UcsQqCQe1G6jRhrAKc2ClyAUdUwwB4w7rlln5Kj4DXp_2nso-c8CtZk5VgfTZBPkpRqq2ag04Yp2VJxQV3KtBYI5lDjb8mwoMUfRZm_Oos1RtCG9uOi5d-cTy24G_y_112wHPp0A6I8-RSimugjJwUmH8Tn-58QL116TOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1924890381</pqid></control><display><type>article</type><title>Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions</title><source>Elsevier</source><creator>Lalu, Lida ; Tambe, Vishakha ; Pradhan, Deepak ; Nayak, Kritika ; Bagchi, Suchandra ; Maheshwari, Rahul ; Kalia, Kiran ; Tekade, Rakesh Kumar</creator><creatorcontrib>Lalu, Lida ; Tambe, Vishakha ; Pradhan, Deepak ; Nayak, Kritika ; Bagchi, Suchandra ; Maheshwari, Rahul ; Kalia, Kiran ; Tekade, Rakesh Kumar</creatorcontrib><description>Ocular discomforts involve anterior/posterior-segment diseases, symptomatic distress and associated inflammations and severe retinal disorders. Conventionally, the formulations such as eye drops, eye solutions, eye ointments and lotions, etc. were used as modalities to attain relief from such ocular discomforts. However, eye allows limited access to these traditional formulations due to its unique anatomical structure and dynamic ocular environment and therefore calls for improvement in disease intervention. To address these challenges, development of nanotechnology based nanomedicines and novel nanosystems (liposomes, cubosomes, polymeric and lipidic nanoparticles, nanoemulsions, spanlastics and nano micelles) are currently in progress (some of them are already marketed such as Eye-logic liposomal eye spray@Naturalife, Ireland). Today, it is one of the central concept in designing more accessible formulations for deeper segments of the eyes. These nanosystems has largely enabled the availability of medicaments at required site in a required concentration without inversely affecting the eye tissues; and therefore, attaining the excessive considerations from the formulation scientists and pharmacologists worldwide. The entrapment of drugs, genes, and proteins inside these novel systems is the basis that works at the bio-molecular level bestows greater potential to eradicate disease causatives. In this review, we highlighted the recent attempts of nanotechnology-based systems for treating and managing various ocular ailments. The progress described herein may pave the way to new, highly effective and vital ocular nanosystems. [Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2017.07.035</identifier><identifier>PMID: 28756272</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Ophthalmic ; Animals ; Biomedical Research ; Eye Diseases - drug therapy ; Humans ; Inflammation - drug therapy ; Nanomedicine ; Nanostructures - administration &amp; dosage ; Nanostructures - therapeutic use ; Ocular barriers ; Ocular diseases ; Ocular nanocarriers ; Ocular nanosystems ; Ocular therapy ; Ophthalmic delivery</subject><ispartof>Journal of controlled release, 2017-12, Vol.268, p.19-39</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-25909338e82d024bd497ff170de8b6841fec892fd7e581c252ce23c3921707483</citedby><cites>FETCH-LOGICAL-c402t-25909338e82d024bd497ff170de8b6841fec892fd7e581c252ce23c3921707483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28756272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lalu, Lida</creatorcontrib><creatorcontrib>Tambe, Vishakha</creatorcontrib><creatorcontrib>Pradhan, Deepak</creatorcontrib><creatorcontrib>Nayak, Kritika</creatorcontrib><creatorcontrib>Bagchi, Suchandra</creatorcontrib><creatorcontrib>Maheshwari, Rahul</creatorcontrib><creatorcontrib>Kalia, Kiran</creatorcontrib><creatorcontrib>Tekade, Rakesh Kumar</creatorcontrib><title>Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Ocular discomforts involve anterior/posterior-segment diseases, symptomatic distress and associated inflammations and severe retinal disorders. Conventionally, the formulations such as eye drops, eye solutions, eye ointments and lotions, etc. were used as modalities to attain relief from such ocular discomforts. However, eye allows limited access to these traditional formulations due to its unique anatomical structure and dynamic ocular environment and therefore calls for improvement in disease intervention. To address these challenges, development of nanotechnology based nanomedicines and novel nanosystems (liposomes, cubosomes, polymeric and lipidic nanoparticles, nanoemulsions, spanlastics and nano micelles) are currently in progress (some of them are already marketed such as Eye-logic liposomal eye spray@Naturalife, Ireland). Today, it is one of the central concept in designing more accessible formulations for deeper segments of the eyes. These nanosystems has largely enabled the availability of medicaments at required site in a required concentration without inversely affecting the eye tissues; and therefore, attaining the excessive considerations from the formulation scientists and pharmacologists worldwide. The entrapment of drugs, genes, and proteins inside these novel systems is the basis that works at the bio-molecular level bestows greater potential to eradicate disease causatives. In this review, we highlighted the recent attempts of nanotechnology-based systems for treating and managing various ocular ailments. The progress described herein may pave the way to new, highly effective and vital ocular nanosystems. [Display omitted]</description><subject>Administration, Ophthalmic</subject><subject>Animals</subject><subject>Biomedical Research</subject><subject>Eye Diseases - drug therapy</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Nanomedicine</subject><subject>Nanostructures - administration &amp; dosage</subject><subject>Nanostructures - therapeutic use</subject><subject>Ocular barriers</subject><subject>Ocular diseases</subject><subject>Ocular nanocarriers</subject><subject>Ocular nanosystems</subject><subject>Ocular therapy</subject><subject>Ophthalmic delivery</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFkE1vEzEQhi1E1aalPwHkI5cN_ljHNheEIqBIVbnA2XLsMXW0awfbW6n_vo4SuCKNNId53hnNg9BbStaU0M2H_XrvciowrRmhck16cfEKraiSfBi1Fq_RqnNq4Buhr9B1rXtCiOCjvERXTEmxYZKt0PSQn2DCyaZcn2uDueKQC26PgFsB22ZIDeeAs1smW3BMYbLzbFvM6SPeLqUc5wdbrI-_e9Ymj8PSlgK4QAVb3CP2sYA7BuobdBHsVOH23G_Qr69ffm7vhvsf375vP98PbiSsDUxoojlXoJgnbNz5UcsQqCQe1G6jRhrAKc2ClyAUdUwwB4w7rlln5Kj4DXp_2nso-c8CtZk5VgfTZBPkpRqq2ag04Yp2VJxQV3KtBYI5lDjb8mwoMUfRZm_Oos1RtCG9uOi5d-cTy24G_y_112wHPp0A6I8-RSimugjJwUmH8Tn-58QL116TOQ</recordid><startdate>20171228</startdate><enddate>20171228</enddate><creator>Lalu, Lida</creator><creator>Tambe, Vishakha</creator><creator>Pradhan, Deepak</creator><creator>Nayak, Kritika</creator><creator>Bagchi, Suchandra</creator><creator>Maheshwari, Rahul</creator><creator>Kalia, Kiran</creator><creator>Tekade, Rakesh Kumar</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20171228</creationdate><title>Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions</title><author>Lalu, Lida ; Tambe, Vishakha ; Pradhan, Deepak ; Nayak, Kritika ; Bagchi, Suchandra ; Maheshwari, Rahul ; Kalia, Kiran ; Tekade, Rakesh Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-25909338e82d024bd497ff170de8b6841fec892fd7e581c252ce23c3921707483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Ophthalmic</topic><topic>Animals</topic><topic>Biomedical Research</topic><topic>Eye Diseases - drug therapy</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Nanomedicine</topic><topic>Nanostructures - administration &amp; dosage</topic><topic>Nanostructures - therapeutic use</topic><topic>Ocular barriers</topic><topic>Ocular diseases</topic><topic>Ocular nanocarriers</topic><topic>Ocular nanosystems</topic><topic>Ocular therapy</topic><topic>Ophthalmic delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lalu, Lida</creatorcontrib><creatorcontrib>Tambe, Vishakha</creatorcontrib><creatorcontrib>Pradhan, Deepak</creatorcontrib><creatorcontrib>Nayak, Kritika</creatorcontrib><creatorcontrib>Bagchi, Suchandra</creatorcontrib><creatorcontrib>Maheshwari, Rahul</creatorcontrib><creatorcontrib>Kalia, Kiran</creatorcontrib><creatorcontrib>Tekade, Rakesh Kumar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lalu, Lida</au><au>Tambe, Vishakha</au><au>Pradhan, Deepak</au><au>Nayak, Kritika</au><au>Bagchi, Suchandra</au><au>Maheshwari, Rahul</au><au>Kalia, Kiran</au><au>Tekade, Rakesh Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2017-12-28</date><risdate>2017</risdate><volume>268</volume><spage>19</spage><epage>39</epage><pages>19-39</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Ocular discomforts involve anterior/posterior-segment diseases, symptomatic distress and associated inflammations and severe retinal disorders. Conventionally, the formulations such as eye drops, eye solutions, eye ointments and lotions, etc. were used as modalities to attain relief from such ocular discomforts. However, eye allows limited access to these traditional formulations due to its unique anatomical structure and dynamic ocular environment and therefore calls for improvement in disease intervention. To address these challenges, development of nanotechnology based nanomedicines and novel nanosystems (liposomes, cubosomes, polymeric and lipidic nanoparticles, nanoemulsions, spanlastics and nano micelles) are currently in progress (some of them are already marketed such as Eye-logic liposomal eye spray@Naturalife, Ireland). Today, it is one of the central concept in designing more accessible formulations for deeper segments of the eyes. These nanosystems has largely enabled the availability of medicaments at required site in a required concentration without inversely affecting the eye tissues; and therefore, attaining the excessive considerations from the formulation scientists and pharmacologists worldwide. The entrapment of drugs, genes, and proteins inside these novel systems is the basis that works at the bio-molecular level bestows greater potential to eradicate disease causatives. In this review, we highlighted the recent attempts of nanotechnology-based systems for treating and managing various ocular ailments. The progress described herein may pave the way to new, highly effective and vital ocular nanosystems. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28756272</pmid><doi>10.1016/j.jconrel.2017.07.035</doi><tpages>21</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2017-12, Vol.268, p.19-39
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_1924890381
source Elsevier
subjects Administration, Ophthalmic
Animals
Biomedical Research
Eye Diseases - drug therapy
Humans
Inflammation - drug therapy
Nanomedicine
Nanostructures - administration & dosage
Nanostructures - therapeutic use
Ocular barriers
Ocular diseases
Ocular nanocarriers
Ocular nanosystems
Ocular therapy
Ophthalmic delivery
title Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T12%3A32%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20nanosystems%20for%20the%20treatment%20of%20ocular%20inflammation:%20Current%20paradigms%20and%20future%20research%20directions&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Lalu,%20Lida&rft.date=2017-12-28&rft.volume=268&rft.spage=19&rft.epage=39&rft.pages=19-39&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2017.07.035&rft_dat=%3Cproquest_cross%3E1924890381%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c402t-25909338e82d024bd497ff170de8b6841fec892fd7e581c252ce23c3921707483%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1924890381&rft_id=info:pmid/28756272&rfr_iscdi=true